<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460706</url>
  </required_header>
  <id_info>
    <org_study_id>77/180/2010</org_study_id>
    <nct_id>NCT01460706</nct_id>
  </id_info>
  <brief_title>Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT</brief_title>
  <acronym>DOTAGLI</acronym>
  <official_title>PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize tumour uptake of somatostatin analog
      68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators
      hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor
      which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor
      uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status
      of the tumor specimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malignant glioma uptake of 68Ga-DOTATOC</measure>
    <time_frame>within 90 minutes post-injection</time_frame>
    <description>PET/CT imaging of the brain starts immediately after the intravenous bolus injection of 68Ga-DOTATOC. Dynamic PET/CT imaging is done over 60-min. A late 90-min scan will be obtained for selected patients. PET studies are analyzed by determining the Standardized Uptake Values (SUV) of the tumor using regions of interest (ROI) drawn both manually and automatically on the tumor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical SST2 receptor status of the tumor specimen</measure>
    <time_frame>After glioma surgery within 4 weeks of PET/CT imaging</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTATOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]DOTATOC</intervention_name>
    <description>120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.</description>
    <arm_group_label>68Ga-DOTATOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 to 70 years old

          -  Language spoken: Finnish or Swedish

          -  Performance status: Karnofsky score 70 or better or WHO performance status 2 or better

          -  Supratentorial malignant glioma based on MRI imaging

          -  Supratentorial recurrent glioma based on MRI and/or [11C]methionine PET imaging

          -  Patients must be able to understand the meaning of the study and sign the appropriate
             Ethical Committee approved informed consent documents in the presence of the
             designated staff

        Exclusion Criteria:

          -  Any medical or psychiatric condition that compromises the subjectÂ´s ability to
             participate in the study

          -  Any other significant disease including liver or renal disease

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki RI Minn, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku PET Centre, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>FI-21100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Heikki Minn</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>68Ga-DOTATOC</keyword>
  <keyword>PET/CT</keyword>
  <keyword>Somatostatin receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

